CommunityNews & Policy

Novo Nordisk’s experimental obesity drug, CagriSema, failed to outperform Eli Lilly’s Zepbound in a head-to-head, phase 3 trial

17 replies13 peopleFeb 23, 2026☆ Follow
Summary

How does CagriSema compare to Zepbound after the head-to-head trial and what do users think about these drugs versus alternatives or stacks?

The trial showed CagriSema reaching 23% weight loss at 84 weeks against 25.5% for tirzepatide, triggering a major stock drop for the maker and confirming the rival drug's lead. Forum users note the numerical gap is small and both remain effective, but debate side-effect differences, muscle loss during weight reduction, and whether older options like semaglutide are truly outdated. Several describe personal stacking experiences and call for better data on body composition changes.

What this discussion establishesWhere people disagree

Whether semaglutide is obsolete or still a solid tool, and how much the trial's small difference actually matters in practice.

Still open

How much of the reported muscle loss is actually intramuscular fat versus contractile tissue, and whether future selective agonists will change tolerability.

Nothing here is advice.

17 replies · 13 people
SharpFenwick93archiveopening postFeb 23

The company's new obesity drug missed its main goal against the rival product in a direct phase 3 comparison, which sent the stock sharply lower. It produced 23 percent weight reduction after 84 weeks while the other agent reached 25.5 percent. That outcome solidifies the competitor as the leading choice for weight reduction. The stock fell more than 16 percent on Monday once the company reported that its next-generation drug had not hit the primary target.

LevelTimber64archiveFeb 23

Even so that percentage still carries weight for me. I know it has nothing to do with the BP Wars yet it counts when patients come into the picture.

SlowBeacon94archiveFeb 23

Weight shifts look about identical across the different sets. It would be great if the research included scans to break down whether the pounds dropped come from fat or lean tissue instead. That detail matters way more for real medical purposes than just the overall scale numbers, since roughly a quarter of what disappears turns out to be muscle.

SharpFenwick93archiveFeb 23

I'm finding this particular pairing effective right now. Each week I inject 4.25 milligrams of the first one on Sunday along with 750 micrograms of the second on Wednesday. The results have been positive so far.

KeenBramble97archiveFeb 23

I'd guess those folks might show stronger outcomes if they weren't stuck resting for several hours each afternoon.

BrightLantern56archiveFeb 24

They look comparable from the descriptions alone yet the unwanted reactions end up varying a lot and suit the dual agonist better. The earliest version has simply become outdated. The amylin addition introduced something fresh but lacks targeted action. Selective versions turn out to produce reactions that people handle more easily. That leaves the blend as an imperfect hybrid. Pairing the triple agonist with a selective amylin option could end up strongest especially when aiming for the lowest possible weight.

LevelTimber64archiveFeb 24

This approach hasn't fallen out of favor yet. Newer options came along afterward, yet the original version still delivers results. Anyone who keeps taking it or combining it with others would say the same thing. It isn't the top choice these days, that's true. Users continue with it anyway because more than one choice exists.

SlowMeadow76archiveFeb 24
↳ replying to @LevelTimber64

My buddy reacted badly to triz because of allergies yet this choice works fine and causes him no trouble.

WarmBramble98archiveFeb 24
↳ replying to @SlowBeacon94

Lately more physicians and weight specialists seem to suggest that what disappears from muscles isn't entirely the tissue itself but rather the fat stored inside. Strength levels appear to hold steady which comes across as a reassuring sign. Still more research is needed and it's premature to draw conclusions. It wouldn't shock me if this turns out accurate.

ClearLedger45archiveFeb 24

It's puzzling to me that folks aren't pairing something that blocks myostatin alongside a glp-1 type drug. That way they could hold onto their muscle or build more even as the fat comes off.

BrightLantern56archiveFeb 24
↳ replying to @ClearLedger45

Right now nothing counts as a reliable myostatin blocker that counts as both proven and cleared for use. Plenty of people in my position keep hoping something suitable appears. Three candidates are moving through studies yet they rely on lab produced antibodies so high costs and no unofficial versions seem likely for years. A handful of peptides get sold with similar claims though their performance and risks look doubtful from what gets shared. For now one substance was paired with an appetite control medication and looked able to keep muscle while body fat came off during a limited early trial at a low dose. Liver values and cholesterol markers still require attention with that option.

IronBramble28archiveFeb 24

Sorry if shareholders in that rival firm took a hit. Joining the trial for the other medication caused me to drop thirty point one percent of my total mass while also packing on serious muscle through weight training.

WarmBramble98archiveFeb 24

Well, not long after this interesting timing.

ClearSparrow87archiveFeb 25

My strong liking for sema hasn't faded. Right now at week three of mixing it with reta the whole thing feels perfect. Honestly these glp compounds come across as pretty similar when it comes to hunger control. Tirz or reta might hold a slight edge by raising energy use though the difference doesn't seem big to me. Without reta on the scene I would still be fine using sema alone. Sema isn't outdated in my eyes just less popular lately and that works out nicely for ongoing use.

SlowLedger42archiveFeb 25
↳ replying to @IronBramble28

I'm invested in this stock so I'm not angry about it. What bothers me is how the rival's drop in value didn't boost ours right away.

SlowBramble78archiveFeb 25
↳ replying to @IronBramble28

Haha I possess quite a bit of LLY and feel alright.

LevelTimber64archiveFeb 25
↳ replying to @ClearSparrow87

Same here. Combining those GLP and GIP options still feels premature to me. The sema option suited me fine until I hit the ceiling. I regret missing out on info about those bigger dose trials back then. At present I've got enough tz on hand to cover me for a while.

ClearBeacon24archiveFeb 26
↳ replying to @ClearSparrow87

It appears many individuals constantly seek the latest attractive item.

Add your experience

If you have tried it, this topic is still open. Sign in to reply — it takes a minute.

Novo Nordisk’s experimental obesity drug, CagriSema, failed to outperform Eli Lilly’s Zepbound in a head-to-head, phase 3 trial · ZyraTrack Community